|
PSCI-21-002 |
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma |
|
PSCI-21-042 |
Prospective evaluation of potential effects of repeated gadoliniumbased contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group ODYSSEY |
|
PSCI-21-062 |
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3Inhibitor Gilteritinib for Patients with FLT3 Mutations |
|
PSCI-21-098 |
NRG-BR007: A Phase III Clinical Trial Evaluating Deescalation of Breast Radiation for Conservative Treatment of Stage I, Hormone sensitive, HER2- Negative Oncotype recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
|
PSCI-21-117 |
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer |
|
PSCI-21-133 |
A mixed-methods implementation evaluation of a pilot study to increase self-sampling for cancer screening: Interviews with previous study participants |
|
PSCI-21-158 |
Radiopaque Hydrogel Rectal Spacer for Prostate Cancer Radiation Image Guidance |
|
PSCI-21-161 |
Adolescent and young adult professional and Olympian athlete cancer survivors |
|
PSCI-21-185 |
Increasing cancer screening among female patients at PSH St. Joseph s residency clinic: Offering a self-sampling option in clinic |
|
PSCI-21-188 |
An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL) |
